Presentation

Company Profile
Senzime is a Swedish medical technology company that develops and markets CE-marked and FDA-approved medical technology systems that assess the patient’s muscle function before, during and after surgery with anaesthesia. Senzime’s system, called TetraGraph®, digitally and continuously measures the degree of neuromuscular blockade in order to prevent complications. Fewer complications lead to less suffering for patients but also contribute to shorter hospital stays and reduced healthcare costs. Senzime’s development portfolio also solutions that enable automated and continuous measurement of biological substances such as glucose and lactate in blood and tissue fluids – CliniSenz® Analyzer and OnZurf® Probe.

Recent highlights
In Q1 2021, Senzime reported net sales of 1,437 (2,589). In March, the company announced that their disposable sensor Tetrasense received right to reimbursement in South Korea. On the same month, the company announced that a study of 120 patients monitored with Tetragraph was published in the Journal of Clinical Anesthesia. In April, the company announced that it continues its expansion of US commercial capacity. In May, Senzime announced that new guidelines in the UK and Ireland suggest quantitative neuromuscular monitoring should be available in every operating site. In June, the company announced that up-listing to Nasdaq main market has been completed.

Outlook
Senzime’s ambition is to become a market leader in the peri- and post-operative neuromuscular monitoring segment, with a market share of over 10%. By 2023, the company’s goal is to reach profitability and to achieve revenue of at least SEK 200 million.